MATTHEW JOHNSON: Open Payments
NPI 1558920330 · LANSING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,687 in 52 payments from 10 companies in 2025. Trend: 2023 $541 · 2024 $1,126 · 2025 $1,687
Food & beverage: $1,687
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $385 |
| ABBVIE INC. | 9 | $309 |
| E.R. Squibb & Sons, L.L.C. | 2 | $215 |
| Janssen Pharmaceuticals, Inc | 3 | $213 |
| Otsuka America Pharmaceutical, Inc. | 11 | $172 |
| Teva Pharmaceuticals USA, Inc. | 1 | $120 |
| Alkermes, Inc. | 5 | $118 |
| Vanda Pharmaceuticals Inc. | 2 | $68 |
| Axsome Therapeutics, Inc. | 2 | $62 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
Products named: CAPLYTA, VRAYLAR, COBENFY, INVEGA SUSTENNA, UZEDY, ARISTADA, ABILIFY MAINTENA, FANAPT.
Industry payments across MI — which companies pay providers there.
